 Home > Medical News > Latest Medical News > AstraZeneca's new generation of PARP inhibitors get clinical approval

AstraZeneca's new generation of PARP inhibitors get clinical approval

 Last Update: 2021-09-12
 Source: Internet
 Author: User

Tags

cornstarch side effects

marquis drug test

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 7, the CDE official website showed that AstraZeneca's PARP1 selective inhibitor was approved for clinical use in advanced malignant solid tumors

It is worth noting that this is a selective inhibitor of PARP1.

From CDE official website

PARP inhibitors have shown excellent clinical efficacy in homologous recombination-deficient cancer patients.

At the 2021AACR meeting, AstraZeneca disclosed the structure and early data of AZD5305 for the first time

In the preclinical toxicology model, AZD5305 showed superior properties to olaparib

In vitro, AZD5305 selectively inhibits the growth of DNA repair pathway-deficient cell lines, with IC50 in the single-digit nM range, while in other cells there is no or almost no growth inhibitory effect (IC50>10μM), which indicates that AZD5305 is clinically It has great potential for improved therapeutic index

From the AACR Annual Meeting

According to the Insight database, AZD5305 first started a phase 1 clinical PETRA study (NCT04644068) abroad in October 2020; and in China, this new drug was approved for clinical use for the first time today

From Insight Global New Drug Database (http://db.

Note: The original text has been deleted

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.